1. Home
  2. LKFN vs DMRA Comparison

LKFN vs DMRA Comparison

Compare LKFN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

HOLD

Current Price

$60.71

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$20.07

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LKFN
DMRA
Founded
1872
2011
Country
United States
United States
Employees
N/A
7
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
LKFN
DMRA
Price
$60.71
$20.07
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$67.00
$43.00
AVG Volume (30 Days)
147.9K
308.5K
Earning Date
04-27-2026
05-11-2026
Dividend Yield
3.49%
N/A
EPS Growth
10.47
N/A
EPS
1.04
N/A
Revenue
$985,000.00
N/A
Revenue This Year
$15.50
N/A
Revenue Next Year
$5.51
N/A
P/E Ratio
$59.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.36
$16.50
52 Week High
$69.38
$28.76

Technical Indicators

Market Signals
Indicator
LKFN
DMRA
Relative Strength Index (RSI) 52.92 33.97
Support Level $60.51 N/A
Resistance Level $60.94 $27.70
Average True Range (ATR) 1.39 1.97
MACD 0.18 -0.30
Stochastic Oscillator 56.20 21.42

Price Performance

Historical Comparison
LKFN
DMRA

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: